Clinical efficacy of micafungin for chronic pulmonary aspergillosis

Medical Mycology

Volumn 45, Issue 3, 2007, Pages 273-278

  Izumikawa, Koichi ^a   Ohtsu, Yoshiko ^a   Kawabata, Masateru ^a   Takaya, Hisashi ^a   Miyamoto, Atsushi ^a   Sakamoto, Susumu ^a   Kishi, Kazuma ^a   Tsuboi, Eiyasu ^a   Homma, Sakae ^a   Yoshimura, Kunihiko ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic pulmonary aspergillosis; Micafungin

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; MICAFUNGIN;

ADULT; AGED; ANOREXIA; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FUNGAL STRAIN; HUMAN; HYPOKALEMIA; LUNG ASPERGILLOSIS; MALE; NEPHROTOXICITY; RETROSPECTIVE STUDY; SEROLOGY;

ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ITRACONAZOLE; JAPAN; LIPOPROTEINS; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

ASPERGILLUS;

EID: 34248205677     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780701278386     Document Type: Article

References (32)

1. Sobel, JD. (2000) Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis, 30, p. 652.
2. Soubani, AO and Chandrasekar, PH. (2002) The clinical spectrum of pulmonary aspergillosis. Chest, 121, pp. 1988-1999.
3. Marr, KA, Patterson, T. and Denning, D. (2002) Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am, 16, pp. 875-894.
4. Hope, WW, Walsh, TJ and Denning, DW. (2005) The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol, 43, p. S207.
5. Saraceno, JL, Phelps, DT, Ferro, TJ, Futerfas, R. and Schwartz, DB. (1997) Chronic necrotizing pulmonary aspergillosis: Approach to management. Chest, 112, pp. 541-548.
6. Pfeiffer, CD, Fine, JP and Safdar, N. (2006) Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis, 42, pp. 1417-1727.
7. Ostrosky-Zeichner, L., Marr, KA, Rex, JH and Cohen, SH. (2003) Amphotericin B: Time for a new "gold standard". Clin Infect Dis, 37, pp. 415-425.
8. Gallis, HA, Drew, RH and Pickard, WW. (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis, 12, pp. 308-329.
9. Tollemar, J., Klingspor, L. and Ringden, O. (2001) Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clin Microbiol Infect, 7, pp. 68-79.
10. Herbrecht, R., Denning, DW and Patterson, TF (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347, pp. 408-415.
11. Chandrasekar, PH and Manavathu, E. (2001) Voriconazole: A second-generation triazole. Drugs Today (Barc), 37, pp. 135-148.
12. Johnson, LB and Kauffman, CA. (2003) Voriconazole: A new triazole antifungal agent. Clin Infect Dis, 36, pp. 630-637.
13. Kartsonis, NA, Nielsen, J. and Douglas, CM. (2003) Caspofungin: The first in a new class of antifungal agents. Drug Resist Update, 6, pp. 197-218.
14. Keating, GM and Jarvis, B. (2001) Caspofungin. Drugs, 61, pp. 1121-1129.
15. Tomishima, M., Ohki, H. and Yamada, A. (1999) FK463, a novel water-soluble echinocandin lipopeptide: Synthesis and antifungal activity. J Antibiot (Tokyo), 52, pp. 674-676.
16. Tawara, S., Ikeda, F. and Maki, K. (2000) In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother, 44, pp. 57-62.
17. Ikeda, F., Wakai, Y. and Matsumoto, S. (2000) Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother, 44, pp. 614-618.
18. Maesaki, S., Hossain, MA and Miyazaki, Y. (2000) Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother, 44, pp. 1728-1730.
19. Matsumoto, S., Wakai, Y. and Nakai, T. (2000) Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother, 44, pp. 619-621.
20. Ostrosky-Zeichner, L., Kontoyiannis, D. and Raffalli, J. (2005) International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis, 24, pp. 654-661.
21. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-849.
22. de Wet, NT, Bester, AJ and Viljoen, JJ (2005) A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther, 21, pp. 899-907.
23. van Burik, JA, Ratanatharathorn, V. and Stepan, DE (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis, 39, pp. 1407-1416.
24. Kohno, S., Masaoka, T. and Yamaguchi, H. (2004) A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis, 36, pp. 372-379.
25. Verweij, PE, Stynen, D. and Rijs, AJ (1995) Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol, 33, pp. 1912-1914.
26. Mori, T. and Matsumura, M. (1999) Clinical evaluation of diagnostic methods using plasma and/or serum for three mycoses: Aspergillosis, candidosis, and pneumocystosis. Nippon Ishinkin Gakkai Zasshi, 40, pp. 223-230.
27. Yokote, T., Akioka, T. and Oka, S. (2004) Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy. Ann Hematol, 83, pp. 64-66.
28. Marr, KA. (2004) Combination antifungal therapy: Where are we now, and where are we going?. Oncology (Huntingt), 18, pp. 24-29.
29. Marr, KA, Boeckh, M., Carter, RA, Kim, HW and Corey, L. (2004) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis, 39, pp. 797-802.
30. Johnson, MD, MacDougall, C., Ostrosky-Zeichner, L., Perfect, JR and Rex, JH. (2004) Combination antifungal therapy. Antimicrob Agents Chemother, 48, pp. 693-715.
31. Petraitis, V., Petraitiene, R. and Sarafandi, AA (2003) Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis, 187, pp. 1834-1843.
32. Luque, JC, Clemons, KV and Stevens, DA. (2003) Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother, 47, pp. 1452-1455.